Gulf Pacific Power Expands Operating Wind Portfolio 2-10-2025, 03:01

BitMEX Debuts New Mobile Trading Experience With Intuitive Design and Controls 11-12-2025, 19:30

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00